3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Fatigue
4
Prostatic Neoplasms
3
Sleep Wake Disorders
2
Neurotoxicity Syndromes
1
Hematologic Neoplasms
1
Depression
1
Cognitive Dysfunction
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Interventions
Memantine
2
lithium sulfate
1
lime
1
fasudil
1
XENP 1595
1
Ramipril
1
Methylphenidate
1
Lithium
1
Infliximab
1
Ibuprofen
1
Exercise
1
Cannabidiol
1
Behavior Therapy
1
Aspirin
1
Ashwagandha
1
Anticonvulsants
1
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cognitive Dysfunction
×
Methylphenidate
×
Clear all
NCT02970500
2023-03-23
CogMet
CHU de Quebec-Universite Laval
Phase 2
Terminated
20 enrolled